

Table of contents

Supporting Information

General Methods	2
General experimental procedure for Ugi tetrazoles (7)	3-6
General experimental procedure for <i>N</i> -Unsubstituted α -aminotetrazoles (8)	7-8
General experimental procedure for the tetrazole-fused keto-piperazines (11)	9-18
Characterization of Products (MS, ^1H NMR and ^{13}C NMR spectra of compounds)	19-72
Computational Library	73-74
Single Crystal X-Ray Structure Determination of Compounds	75-82

Experimental section


General methods

Nuclear magnetic resonance spectra (NMR) were recorded on a Bruker Avance 500 spectrometer (^1H NMR (500 MHz), ^{13}C NMR (126 MHz)). Chemical shifts for ^1H NMR were reported as δ values and coupling constants were in hertz (Hz). The following abbreviations were used for spin multiplicity: s = singlet, d = doublet, t = triplet, dd = double doublet, m = multiplet, bs = broad singlet. Chemical shifts for ^{13}C NMR reported in ppm relative to the solvent peak. Thin layer chromatography was performed on Fluka precoated silica gel plates (0.20 mm thick, particle size 25 μm). Flash chromatography was performed on a Teledyne ISCO Combiflash Rf, using RediSep Rf Normal-phase Silica Flash Columns (Silica Gel 60 Å, 230 - 400 mesh). Reagents were available from commercial suppliers and used without any purification unless otherwise noted. All isocyanides were made in house by either performing the Hoffman or Ugi procedure. Other reagents were purchased from Sigma Aldrich, ABCR, Acros and AK Scientific and were used without further purification. All microwave irradiation reactions were carried out in a Biotage InitiatorTM Microwave Synthesizer. Electrospray ionization mass spectra (ESI-MS) were recorded on a Waters Investigator Semi-prep 15 SFC-MS instrument.

Synthetic procedure A

Aldehyde (1 mmol), tritylamine (1 mmol) were mixed in methanol (1 mL) and subjected to microwave irradiation for 15 minutes. Subsequently isocyanide (1mmol) and azidotrimethylsilane (1 mmol) were added and the mixture was stirred at room temperature for 18h. The solvent was evaporated under reduced pressure and the residue was purified using flash chromatography to obtain the desired product.


Methyl 2-((tritylamino)methyl)-1H-tetrazol-1-yl)acetate (7a):



The product was obtained using procedure A. Yield: 82%.

¹H NMR (500 MHz, CDCl₃) δ 7.41 (d, *J* = 7.8 Hz, 6H), 7.30 (d, *J* = 7.8 Hz, 6H), 7.22 (m, 3H), 5.15 (s, 2H), 3.77 (d, *J* = 7.4 Hz, 2H), 3.74 (s, 3H), 2.57 (t, *J* = 7.5 Hz, 1H). ¹³C NMR (126 MHz, CDCl₃) δ 166.0, 154.4, 144.3, 128.4, 128.1, 127.8, 127.1, 126.9, 71.1, 53.1, 48.0, 37.2. MS (ESI) m/z calculated for C₂₄H₂₃N₅O₂ : [M]⁺: 413.18; found [M-H]⁺: 412.24.

Methyl 2-(5-(2-methyl-1-(tritylamino)propyl)-1H-tetrazol-1-yl)acetate (7b):




The product was obtained using procedure A. Yield: 68%.

¹H NMR (500 MHz, CDCl₃) δ 7.35 (d, *J* = 7.7 Hz, 6H), 7.19 (t, *J* = 7.7 Hz, 6H), 7.14 (t, *J* = 7.1 Hz, 3H), 4.78 (d, *J* = 17.6 Hz, 1H), 4.22 (d, *J* = 17.6 Hz, 1H), 3.81 (dd, *J* = 7.7, 5.3 Hz, 1H), 3.69 (s, 3H), 2.98 (d, *J* = 7.7 Hz, 1H), 2.33 – 2.23 (m, 1H), 1.01 (d, *J* = 6.8 Hz, 3H), 0.73 (d, *J* = 6.9 Hz, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 165.6, 156.3, 144.9, 128.4, 127.8, 127.1, 126.7, 71.3, 53.3, 52.8, 47.7, 34.6, 19.1, 17.3.

MS (ESI) m/z calculated for C₂₇H₂₉N₅O₂: [M]⁺: 455.23; found [M-H]⁺: 454.34.

Methyl 2-(5-(2-phenyl-1-(tritylamino)ethyl)-1*H*-tetrazol-1-yl)acetate (7c):




The product was obtained using procedure A. Yield: 74%.

¹H NMR (500 MHz, CDCl₃) δ 7.29 – 7.25 (m, 4H), 7.25 – 7.20 (m, 6H), 7.17 – 7.12 (m, 8H), 7.02 – 6.99 (m, 2H), 4.65 (d, *J* = 17.5 Hz, 1H), 4.22 – 4.14 (m, 1H), 4.05 (d, *J* = 17.5 Hz, 1H), 3.66 (s, 3H), 3.05 (d, *J* = 7.0 Hz, 1H), 2.99 (d, *J* = 7.0 Hz, 2H). ¹³C NMR (126 MHz, CDCl₃) δ 165.5, 157.9, 144.7, 136.2, 129.7, 128.8, 128.5, 128.0, 127.9, 127.8, 127.2, 126.8, 126.5, 71.4, 52.9, 50.9, 47.4, 43.6.

MS (ESI) m/z calculated for C₃₁H₂₉N₅O₂: [M]⁺: 503.23; found [M-H]⁺: 502.25.

Methyl 3-phenyl-2-(5-((tritylamino)methyl)-1*H*-tetrazol-1-yl)propanoate (7d):




The product was obtained using procedure A. Yield: 85%.

¹H NMR (500 MHz, CDCl₃) δ 7.33 (d, *J* = 8.0 Hz, 6H), 7.29 (t, *J* = 8.0 Hz, 6H), 7.26 – 7.22 (m, 3H), 7.14 – 7.10 (m, 3H), 6.88 – 6.83 (m, 2H), 5.36 (dd, *J* = 9.5, 6.5 Hz, 1H), 3.76 (s, 3H), 3.64 – 3.59 (m, 2H), 3.45 (dd, *J* = 14.0, 6.5 Hz, 1H), 3.26 (dd, *J* = 14.0, 8.4 Hz, 1H), 2.15 (t, *J* = 7.2 Hz,

1H). ^{13}C NMR (126 MHz, CDCl_3) δ 167.4, 154.4, 144.2, 135.0, 128.8, 128.7, 128.6, 128.4, 128.3, 128.2, 128.1, 127.8, 127.7, 127.4, 127.1, 126.9, 70.9, 61.7, 53.3, 36.8, 36.5.

MS (ESI) m/z calculated for $\text{C}_{31}\text{H}_{29}\text{N}_5\text{O}_2$: $[\text{M}]^+$: 503.23; found $[\text{M}-\text{H}]^+$: 502.25.

Methyl 2-phenyl-2-(5-((tritylamino)methyl)-1H-tetrazol-1-yl)acetate (7e):




The product was obtained using procedure A. Yield: 71%.

^1H NMR (500 MHz, CDCl_3) δ 7.42 (d, $J = 8.1$ Hz, 6H), 7.38 – 7.27 (m, 9H), 7.24 (dd, $J = 12.8$, 5.4 Hz, 4H), 7.18 (d, $J = 7.3$ Hz, 2H), 6.50 (s, 1H), 3.78 (s, 3H), 3.66 (dd, $J = 14.4$, 6.2 Hz, 1H), 3.49 (dd, $J = 14.4$, 8.1 Hz, 1H), 2.55 (t, $J = 7.4$ Hz, 1H). ^{13}C NMR (126 MHz, CDCl_3) δ 167.0, 154.1, 144.4, 131.5, 129.7, 129.1, 128.7, 128.5, 128.4, 128.1, 126.8, 71.0, 63.9, 53.4, 37.4.

MS (ESI) m/z calculated for $\text{C}_{30}\text{H}_{27}\text{N}_5\text{O}_2$: $[\text{M}]^+$: 489.22; found $[\text{M}-\text{H}]^+$: 488.27.

Methyl 3-(1H-indol-3-yl)-2-(5-((tritylamino)methyl)-1H-tetrazol-1-yl)propanoate (7f):



The product was obtained using procedure A. Yield: 78%.

^1H NMR (500 MHz, CDCl_3) δ 8.31 (bs, 1H), 7.30 (d, $J = 7.5$ Hz, 1H), 7.24 – 7.08 (m, 18H), 7.01 (t, $J = 7.5$ Hz, 1H), 6.48 (d, $J = 2.1$ Hz, 1H), 5.39 (dd, $J = 11.3$, 3.9 Hz, 1H), 3.81 (dd, $J = 15.0$, 3.8 Hz, 1H), 3.76 (s, 3H), 3.70 (dd, $J = 15.0$, 11.4 Hz, 1H), 3.12 – 3.03 (m, 2H). ^{13}C NMR (126


MHz, CDCl₃) δ 167.6, 154.8, 144.3, 135.9, 128.3, 128.2, 128.1, 128.0, 126.7, 126.0, 123.5, 122.3, 119.9, 117.4, 111.6, 108.5, 70.9, 60.7, 53.3, 36.5, 27.4.

MS (ESI) m/z calculated for C₃₃H₃₀N₆O₂: [M]⁺: 542.24; found [M-H]⁺: 541.32.

Synthetic procedure B

The Ugi tetrazole (1.0 mmol) was added to 6N HCl solution (5mL) and heated for 18h at 80°C. The precipitate was filtrated off and the filtrate was evaporated under reduced pressure to give the corresponding tetrazole aminoacid. Which was neutralized to pH 7 with dilute aq. NH₃ and the water was evaporated to dryness.

2-(5-(aminomethyl)-1H-tetrazol-1-yl)acetic acid (8a):




The product was obtained using procedure **B**. Yield: 82 %

¹H NMR (500 MHz, MeOD) δ 5.47 (s, 2H), 4.55 (s, 2H) ppm. ¹³C NMR (126 MHz, MeOD) δ 168.9, 152.4, 49.6, 34.2.

MS (ESI) m/z calculated for C₄H₇N₅O₂: [M]⁺: 157.13; found [M-H]⁺: 156.

2-(5-(1-amino-2-methylpropyl)-1H-tetrazol-1-yl)acetic acid (8b):




The product was obtained using procedure **B**. Yield: 95 %

¹H NMR (500 MHz, MeOD) δ 5.57 (d, *J* = 18.0 Hz, 1H), 5.44 (d, *J* = 18.0 Hz, 1H), 4.72 (d, *J* = 7.6 Hz, 1H), 2.51 – 2.42 (m, 1H), 1.12 (d, *J* = 6.8 Hz, 3H), 0.99 (d, *J* = 6.8 Hz, 3H). ¹³C NMR (126 MHz, MeOD) δ 168.9, 154.6, 51.0, 49.7, 33.0, 18.9, 18.5.

MS (ESI) m/z calculated for C₇H₁₃N₅O₂: [M]⁺: 199.11; found [M-H]⁺: 198.

2-(5-(1-amino-2-phenylethyl)-1H-tetrazol-1-yl)acetic acid (8c):




The product was obtained using procedure **B**. Yield: 76 %

^1H NMR (500 MHz, MeOD) δ 7.36-7.31 (m, 3H), 7.18-7.12 (m, 2H), 5.20 (d, $J = 18.0$ Hz, 1H), 5.13 (t, $J = 7.8$ Hz, 1H), 4.61 (d, $J = 18.0$ Hz, 1H), 3.78 (s, 2H), 3.46 (dd, $J = 13.5, 6.8$ Hz, 1H), 3.36-3.28 (m, 1H). ^{13}C NMR (126 MHz, MeOD) δ 168.6, 154.5, 134.8, 130.7, 130.2, 129.2, 49.0, 47.5, 40.0.

MS (ESI) m/z calculated for $\text{C}_{11}\text{H}_{13}\text{N}_5\text{O}_2$: [M] $^+$: 247.11; found [M-H] $^+$: 246.

2-(5-(aminomethyl)-1H-tetrazol-1-yl)-3-phenylpropanoic acid (8d):




The product was obtained using procedure **B**. Yield: 85 %.

^1H NMR (500 MHz, MeOD) δ 7.28-7.19 (m, 3H), 7.13 (d, $J = 8.0$ Hz, 2H), 5.82 (dd, $J = 11.0, 4.4$ Hz, 1H), 4.33 (d, $J = 16.3$ Hz, 1H), 3.91 (d, $J = 16.3$ Hz, 1H), 3.78 (dd, $J = 14.4, 4.4$ Hz, 1H), 3.56 (dd, $J = 14.4, 11.1$ Hz, 1H). ^{13}C NMR (126 MHz, MeOD) δ 169.1, 151.7, 136.4, 129.9, 129.7, 128.3, 63.5, 37.5, 34.8.

MS (ESI) m/z calculated for $\text{C}_{11}\text{H}_{13}\text{N}_5\text{O}_2$: [M] $^+$: 247.11; found [M-H] $^+$: 246.

2-(5-(aminomethyl)-1H-tetrazol-1-yl)-2-phenylacetic acid (8e):




The product was obtained using procedure **B**. Yield: 78%.

^1H NMR (500 MHz, MeOD) δ 7.53 – 7.48 (m, 5H), 6.93 (s, 1H), 4.54 (d, J = 16.3 Hz, 1H), 4.05 (d, J = 16.3 Hz, 1H). ^{13}C NMR (126 MHz, MeOD) δ 177.6, 160.3, 142.1, 139.4, 138.8, 138.2, 72.6, 41.7.

MS (ESI) m/z calculated for $\text{C}_{10}\text{H}_{11}\text{N}_5\text{O}_2$: [M] $^+$: 233.09; found [M+H] $^+$: 234.

2-(5-(aminomethyl)-1H-tetrazol-1-yl)-3-(1H-indol-3-yl)propanoic acid (8f):



The product was obtained using procedure **B**. Yield: 70 %

^1H NMR (500 MHz, MeOD) δ 7.45 (d, J = 7.9 Hz, 1H), 7.34 (d, J = 7.9 Hz, 1H), 7.12 (t, J = 7.5 Hz, 1H), 7.04 (t, J = 7.5 Hz, 1H), 6.89 (s, 1H), 5.85 (dd, J = 10.5, 4.4 Hz, 1H), 4.07 (d, J = 16.2 Hz, 1H), 3.87 (dd, J = 15.1, 4.4 Hz, 1H), 3.73 (dd, J = 15.1, 10.5 Hz, 1H), 3.54 (d, J = 16.2 Hz, 1H) ppm. ^{13}C NMR (126 MHz, MeOD) δ 169.9, 151.9, 137.7, 127.7, 125.0, 122.9, 120.4, 118.5, 112.7, 109.1, 63.2, 34.0, 28.3.


MS (ESI) m/z calculated for $\text{C}_{13}\text{H}_{14}\text{N}_6\text{O}_2$: [M] $^+$: 286.12; found [M-H] $^+$: 285.

Synthetic procedure C

The mixture of tetrazole aminoacid (1 mmol), aldehyde (1 mmol) and isocyanide (1mmol) in 2,2,2-Trifluoroethanol (TFE) (1mL) was subjected to microwave irradiation for 30 minutes at 120 °C. The solvent was evaporated under reduced pressure and the residue was purified using flash chromatography to obtain the desired product.

In all the cases, the spectral data are given for the major diastereomer

N-(tert-butyl)-2-(4-fluorophenyl)-2-(6-oxo-5,6-dihydrotetrazolo[1,5-a]pyrazin-7(8H)-yl)acetamide (11a):




The product was obtained using procedure C. Yield: 45%.

^1H NMR (500 MHz, CDCl_3) δ 7.43 – 7.35 (m, 2H), 7.18 – 7.10 (m, 2H), 6.22 (s, 1H), 5.96 (s, 1H), 5.27 (d, $J = 17.0$ Hz, 1H), 5.15 (s, 2H), 4.28 (d, $J = 17.0$ Hz, 1H), 1.36 (s, 9H). ^{13}C NMR (126 MHz, CDCl_3) δ 167.5, 163.1 ($J = 250.7$ Hz), 161.4, 147.2, 131.6 ($J = 8.4$ Hz), 128.4 ($J = 3.4$ Hz), 116.6 ($J = 21.7$ Hz), 59.8, 52.2, 47.8, 39.5, 28.5.

MS (ESI) m/z calculated for $\text{C}_{16}\text{H}_{19}\text{FN}_6\text{O}_2$: $[\text{M}]^+$: 346.16; found $[\text{M}-\text{H}]^+$: 345.16.

2-(5-((1H-indol-3-yl)methyl)-6-oxo-5,6-dihydrotetrazolo[1,5-a]pyrazin-7(8H)-yl)-N-(tert-butyl)-2-(4-fluorophenyl)acetamide (11n):




The product was obtained using procedure C. Yield: 20%.

¹H NMR (500 MHz, MeOD) δ 7.42 (d, *J* = 8.2 Hz, 1H), 7.37 (d, *J* = 8.0 Hz, 1H), 7.23 (t, *J* = 7.7 Hz, 1H), 7.09 (t, *J* = 7.7 Hz, 1H), 6.91 (t, *J* = 8.5 Hz, 2H), 6.39 – 6.35 (m, 2H), 6.19 (s, 1H), 5.83 (s, 1H), 5.78 – 5.74 (m, 1H), 4.60 (s, 1H), 4.51 (dd, *J* = 16.8, 1.2 Hz, 1H), 3.99 (dd, *J* = 14.9, 3.0 Hz, 1H), 3.65 (dd, *J* = 14.9, 4.0 Hz, 1H), 2.72 (dd, *J* = 16.8, 1.2 Hz, 1H), 1.32 (s, 9H). ¹³C NMR (126 MHz, MeOD) δ 170.5, 164.1 (*J* = 247.8 Hz), 149.6, 132.6 (*J* = 8.5 Hz), 128.5, 124.9, 123.0, 120.7, 119.1, 116.7 (*J* = 21.9 Hz), 112.8, 107.3, 61.7, 61.3, 52.5, 40.9, 30.5, 28.7.

MS (ESI) m/z calculated for C₂₅H₂₆FN₇O₂ : [M]⁺: 475.21; found [M-H]⁺: 474.25.

2-(4-bromophenyl)-N-(tert-butyl)-2-(8-isopropyl-6-oxo-5,6-dihydrotetrazolo[1,5-a]pyrazin-7(8H)-yl)acetamide (11b):




The product was obtained using procedure C. Yield: 53%.

¹H NMR (500 MHz, CDCl₃) δ 7.60 (d, *J* = 8.4 Hz, 2H), 7.33 (d, *J* = 8.4 Hz, 2H), 5.81 (s, 1H), 5.56 (s, 1H), 5.24 (d, *J* = 17.9 Hz, 1H), 5.10 (d, *J* = 17.9 Hz, 1H), 4.46 (d, *J* = 3.0 Hz, 1H), 2.71 – 2.60 (m, 1H), 1.36 (s, 9H), 0.89 (d, *J* = 7.0 Hz, 3H), 0.63 (d, *J* = 7.0 Hz, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 166.8, 162.5, 148.7, 132.7, 131.7, 131.2, 124.2, 64.9, 57.1, 52.0, 48.4, 33.1, 28.4, 18.4, 15.1.

MS (ESI) m/z calculated for C₁₉H₂₅BrN₆O₂ : [M]⁺: 448.12; found [M-H]⁺: 447.14.

N-cyclohexyl-2-(8-isopropyl-6-oxo-5,6-dihydrotetrazolo[1,5-a]pyrazin-7(8H)-yl)-4-phenylbutanamide (11c):




The product was obtained using procedure C. Yield: 33%.

¹H NMR (500 MHz, CDCl₃) δ 7.22 (t, *J* = 7.5 Hz, 2H), 7.16 – 7.07 (m, 3H), 6.85 (d, *J* = 8.0 Hz, 1H), 5.15 (d, *J* = 18.1 Hz, 1H), 5.04 (d, *J* = 3.4 Hz, 1H), 4.99 (d, *J* = 18.1 Hz, 1H), 4.87 (t, *J* = 7.2 Hz, 1H), 3.82 – 3.73 (m, 1H), 2.75 – 2.66 (m, 1H), 2.65 – 2.56 (m, 1H), 2.56 – 2.46 (m, 2H), 2.05 – 1.96 (m, 1H), 1.96 – 1.89 (m, 1H), 1.87 – 1.80 (m, 1H), 1.77 – 1.56 (m, 3H), 1.44 – 1.31 (m, 2H), 1.30 – 1.12 (m, 3H), 1.10 (d, *J* = 7.0 Hz, 3H), 0.52 (d, *J* = 7.0, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 168.2, 163.7, 148.0, 139.7, 128.4, 128.1, 126.3, 57.0, 55.6, 48.2, 32.6, 32.4, 32.0, 28.3, 25.3, 24.5, 18.7, 15.1.

MS (ESI) m/z calculated for C₂₃H₃₂N₆O₂: [M]⁺: 424.26; found [M-H]⁺: 423.26.

Methyl 2-(2-(4-chlorophenyl)-2-(8-isopropyl-6-oxo-5,6-dihydrotetrazolo[1,5-a]pyrazin-7(8H)-yl)acetamido)acetate (11d):




The product was obtained using procedure C. Yield: 58%.

¹H NMR (500 MHz, CDCl₃) δ 7.49 (d, *J* = 8.5 Hz, 2H), 7.42 (d, *J* = 8.5 Hz, 2H), 6.56 (t, *J* = 5.2 Hz, 1H), 5.67 (s, 1H), 5.25 (d, *J* = 17.8 Hz, 1H), 5.10–5.07 (m, 1H), 5.04 (d, *J* = 17.8 Hz, 1H), 4.01 (d, *J* = 5.4 Hz, 2H), 3.71 (s, 3H), 1.99 – 1.90 (m, 1H), 0.95 (d, *J* = 7.0 Hz, 3H), 0.60 (d, *J* = 7.0 Hz, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 169.8, 168.0, 162.8, 148.5, 136.0, 131.5, 131.0, 129.7, 64.1, 59.0, 52.4, 48.5, 41.4, 33.3, 18.6, 15.0.

MS (ESI) m/z calculated for C₁₈H₂₁ClN₆O₄: [M]⁺: 420.13; found [M-H]⁺: 419.14.

1-(8-isopropyl-6-oxo-5,6-dihydrotetrazolo[1,5-a]pyrazin-7(8H)-yl)-N-(4-methoxyphenethyl)cyclohexanecarboxamide (11e):




The product was obtained using procedure C. Yield: 32%.

¹H NMR (500 MHz, CDCl₃) δ 7.23 (m, 1H), 7.12 (d, *J* = 8.0 Hz, 2H), 6.82 (d, *J* = 8.0 Hz, 2H), 5.21 (s, 1H), 5.11 (d, *J* = 18.0 Hz, 1H), 4.87 (d, *J* = 18.0 Hz, 1H), 3.78 (s, 3H), 3.58 – 3.42 (m, 2H), 2.77 (t, *J* = 6.8 Hz, 2H), 2.62 – 2.53 (m, 1H), 2.52 – 2.44 (m, 1H), 2.39 – 2.30 (m, 1H), 2.17 – 2.09 (m, 1H), 1.92 – 1.79 (m, 2H), 1.56 – 1.33 (m, 5H), 1.07 (d, *J* = 6.8 Hz, 3H), 0.53 (d, *J* = 6.8 Hz, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 172.4, 163.9, 158.1, 148.8, 130.8, 129.6, 113.8, 67.4, 55.6, 55.1, 48.7, 41.0, 34.4, 33.8, 32.9, 32.0, 25.0, 22.5, 22.2, 18.7, 14.8.

MS (ESI) m/z calculated for C₂₃H₃₂N₆O₃: [M]⁺: 440.25; found [M-H]⁺: 439.33.

2-(8-benzyl-6-oxo-5,6-dihydrotetrazolo[1,5-a]pyrazin-7(8H)-yl)-N-(2-methoxy-4-nitrophenyl)-4-phenylbutanamide (11f):




The product was obtained using procedure C. Yield: 72%.

¹H NMR (500 MHz, CDCl₃) δ 9.62 (s, 1H), 8.70 (d, *J* = 9.0 Hz, 1H), 7.98 (dd, *J* = 9.0, 2.4 Hz, 1H), 7.85 (d, *J* = 2.4 Hz, 1H), 7.25 – 7.04 (m, 6H), 6.96 – 6.88 (m, 2H), 6.43 (d, *J* = 7.3 Hz, 1H), 6.33 (d, *J* = 7.3 Hz, 1H), 5.66 (t, *J* = 3.4 Hz, 1H), 5.10 (t, *J* = 7.0 Hz, 1H), 4.65 (d, *J* = 17.7 Hz, 1H), 4.08 (s, 3H), 3.41 (dd, *J* = 14.4, 4.0 Hz, 1H), 3.16 (dd, *J* = 14.2, 4.0 Hz, 1H), 2.99 (d, *J* = 17.7 Hz, 1H), 2.81 – 2.74 (m, 1H), 2.73 – 2.67 (m, 1H), 2.66 – 2.58 (m, 1H), 2.26 – 2.17 (m, 1H). ¹³C NMR (126 MHz, CDCl₃) δ 167.9, 164.5, 150.0, 148.1, 143.9, 139.2, 133.0, 132.3, 129.7, 128.8, 128.7, 128.1, 127.8, 126.6, 119.0, 117.6, 105.5, 58.0, 56.7, 50.6, 47.4, 40.0, 32.3, 28.7.

MS (ESI) m/z calculated for C₂₈H₂₇N₇O₅: [M]⁺: 541.20; found [M-H]⁺: 540.23.

2-(8-benzyl-6-oxo-5,6-dihydrotetrazolo[1,5-a]pyrazin-7(8H)-yl)-N-(4-methoxy-2-nitrophenyl)-3-phenylpropanamide (11g):




The product was obtained using procedure C. Yield: 36%.

¹H NMR (500 MHz, CDCl₃) δ 10.23 (s, 1H), 8.58 (d, *J* = 9.3 Hz, 1H), 7.71 (dd, *J* = 6.4, 2.8 Hz, 2H), 7.66 – 7.59 (m, 4H), 7.33 – 7.27 (m, 1H), 7.25 – 7.17 (m, 3H), 6.66 (d, *J* = 7.4 Hz, 2H), 6.23 (s, 1H), 5.66 (t, *J* = 3.5 Hz, 1H), 4.77 (d, *J* = 17.4 Hz, 1H), 3.85 (s, 3H), 3.04 (d, *J* = 17.4 Hz, 1H), 2.87 (dd, *J* = 14.0, 3.5 Hz, 1H), 2.50 (dd, *J* = 14.0, 3.5 Hz, 1H). ¹³C NMR (126 MHz, CDCl₃) δ 166.9, 163.5, 155.5, 150.3, 137.2, 131.6, 130.8, 130.4, 130.2, 130.0, 129.0, 128.2, 127.5, 123.6, 123.2, 108.8, 64.7, 55.9, 52.7, 47.7, 40.4.

MS (ESI) m/z calculated for C₂₆H₂₃N₇O₅: [M]⁺: 513.18; found [M-H]⁺: 512.33.

2-(5-benzyl-6-oxo-5,6-dihydrotetrazolo[1,5-a]pyrazin-7(8H)-yl)-2-(4-cyanophenyl)-N-phenethylacetamide (11i):




The product was obtained using procedure C. Yield: 33%.

¹H NMR (500 MHz, CDCl₃) δ 7.55 (d, *J* = 8.3 Hz, 2H), 7.34 – 7.08 (m, 8H), 7.02 – 6.95 (m, 2H), 6.50 (d, *J* = 7.2 Hz, 2H), 6.21 (s, 1H), 6.04 (t, *J* = 5.8 Hz, 1H), 5.56 (t, *J* = 3.7 Hz, 1H), 4.82 (dd, *J* = 17.0 Hz, 1.0, 1H), 3.86 (d, *J* = 17.0 Hz, 1H), 3.79 – 3.50 (m, 4H), 2.80 (td, *J* = 6.8, 2.5 Hz, 2H). ¹³C NMR (126 MHz, CDCl₃) δ 166.7, 163.6, 147.2, 138.0, 137.1, 132.6, 132.5, 129.6, 129.0, 128.9, 128.6, 128.4, 128.0, 126.5, 117.7, 112.8, 60.0, 58.8, 40.3, 38.9, 38.8, 35.0.

MS (ESI) m/z calculated for C₂₈H₂₅N₇O₂: [M]⁺: 491.21; found [M+H]⁺: 492.28.

2-(5-benzyl-6-oxo-5,6-dihydrotetrazolo[1,5-a]pyrazin-7(8H)-yl)-2-(4-bromophenyl)-N-(tert-butyl)acetamide (11j):




The product was obtained using procedure C. Yield: 40%.

¹H NMR (500 MHz, CDCl₃) δ 7.50 (d, *J* = 8.4 Hz, 2H), 7.26 – 7.23 (m, 1H), 7.19 – 7.11 (m, 2H), 7.02 – 6.94 (m, 2H), 6.54 (d, *J* = 7.7 Hz, 2H), 6.04 (s, 1H), 5.68 – 5.56 (m, 1H), 5.41 (s, 1H), 4.93 (d, *J* = 16.6 Hz, 1H), 3.68 (dd, *J* = 14.0, 3.1 Hz, 1H), 3.60 (dd, *J* = 14.0, 4.4 Hz, 1H), 3.02 (d, *J* = 16.6, 1H), 1.33 (s, 9H). ¹³C NMR (126 MHz, CDCl₃) δ 166.7, 164.6, 147.8, 132.4, 132.2, 131.0, 130.7, 129.0, 128.9, 128.6, 127.9, 123.6, 60.3, 60.0, 52.0, 39.1, 38.3, 28.5.

MS (ESI) m/z calculated for C₂₃H₂₅BrN₆O₂: [M]⁺: 496.12; found [M-H]⁺: 495.23.

N-(tert-butyl)-2-(4-chlorophenyl)-2-(6-oxo-5-phenyl-5,6-dihydrotetrazolo[1,5-a]pyrazin-7(8H)-yl)acetamide (11m):




The product was obtained using procedure C. Yield: 42%.

¹H NMR (500 MHz, CDCl₃) δ 7.41 – 7.36 (m, 4H), 7.36 – 7.29 (m, 3H), 7.04 (d, *J* = 7.3 Hz, 2H), 6.28 (s, 1H), 6.23 (s, 1H), 5.96 (bs, 1H), 5.31 (dd, *J* = 17.3, 1.0 Hz, 1H), 4.26 (dd, *J* = 17.3, 1.0 Hz, 1H), 1.30 (s, 9H). ¹³C NMR (126 MHz, CDCl₃) δ 167.3, 163.6, 147.2, 135.7, 134.0, 131.0, 130.9, 130.7, 129.7, 129.4, 126.7, 62.9, 60.4, 52.1, 39.1, 28.3.

MS (ESI) m/z calculated for C₂₂H₂₃ClN₆O₂: [M]⁺: 438.16; found [M-H]⁺: 437.17.

2-(5-benzyl-6-oxo-5,6-dihydrotetrazolo[1,5-a]pyrazin-7(8H)-yl)-N-(4-methoxyphenethyl)-2-(4-nitrophenyl)acetamide (11h):




The product was obtained using procedure C. Yield: 37%.

¹H NMR (500 MHz, CDCl₃) δ 8.09 (d, *J* = 8.6 Hz, 2H), 7.16 (t, *J* = 7.3 Hz, 1H), 7.06 – 6.99 (m, 6H), 6.76 (d, *J* = 8.6 Hz, 2H), 6.53 (d, *J* = 7.1 Hz, 2H), 6.22 (s, 1H), 5.93 (t, *J* = 5.7 Hz, 1H), 5.59 (t, *J* = 3.7 Hz, 1H), 4.87 (dd, *J* = 16.7, 1.2 Hz, 1H), 3.76 (s, 3H), 3.70 – 3.63 (m, 2H), 3.63 – 3.50 (m, 2H), 3.11 (dd, *J* = 16.7, 1.2 Hz, 1H), 2.81 – 2.68 (m, 2H). ¹³C NMR (126 MHz, CDCl₃) δ 166.7, 163.8, 158.4, 158.4, 148.1, 147.2, 138.9, 132.8, 130.2, 129.6, 129.2, 128.8, 128.0, 124.0, 114.0, 60.1, 58.7, 55.2, 40.6, 39.1, 38.9, 34.3.

MS (ESI) m/z calculated for C₂₈H₂₇N₇O₅: [M]⁺: 541.21; found [M-H]⁺: 540.16.

N-(4-methoxy-2-nitrophenyl)-4-methyl-2-(6-oxo-5-phenyl-5,6-dihydrotetrazolo[1,5-a]pyrazin-7(8H)-yl)pentanamide (11k):




The product was obtained using procedure C. Yield: 44%.

¹H NMR (500 MHz, CDCl₃) δ 10.37 (s, 1H), 8.48 (d, *J* = 9.3 Hz, 1H), 7.57 (d, *J* = 2.8 Hz, 1H), 7.39 (dd, *J* = 7.4, 2.8 Hz, 2H), 7.34 – 7.30 (m, 1H), 7.22 – 7.17 (m, 2H), 7.16 – 7.12 (m, 1H), 6.50 (s, 1H), 5.48 – 5.40 (m, 1H), 5.19 (d, *J* = 17.2 Hz, 1H), 4.89 (d, *J* = 17.2 Hz, 1H), 3.83 (s, 3H), 2.00 – 1.88 (m, 2H), 1.56 – 1.42 (m, 1H), 0.98 (d, *J* = 6.8 Hz, 3H), 0.88 (d, *J* = 6.8 Hz, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 167.7, 164.0, 155.6, 146.9, 137.6, 133.5, 129.7, 129.4, 126.4, 124.0, 122.9, 108.8, 63.0, 55.9, 38.6, 36.0, 25.1, 22.9, 21.5.

MS (ESI) m/z calculated for C₂₃H₂₅N₇O₅:[M]⁺: 479.19; found [M-H]⁺: 478.17.

1-(5-((1H-indol-3-yl)methyl)-6-oxo-5,6-dihydrotetrazolo[1,5-a]pyrazin-7(8H)-yl)-N-(4-methoxyphenethyl)cyclohexanecarboxamide (11o):




The product was obtained using procedure C. Yield: 49%.

¹H NMR (500 MHz, DMSO) δ 7.59 (bs, 1H), 7.26 (d, *J* = 8.0 Hz, 1H), 7.17 (d, *J* = 8.0 Hz, 1H), 7.05 (d, *J* = 8.4 Hz, 2H), 6.98 (t, *J* = 7.7 Hz, 1H), 6.89 (d, *J* = 8.4 Hz, 1H), 6.85 – 6.79 (m, 2H), 6.58 (s, 1H), 5.48 (s, 1H), 4.73 (d, *J* = 16.3 Hz, 1H), 3.84 (d, *J* = 16.3 Hz, 1H), 3.70 (s, 3H), 3.69 – 3.64 (m, 1H), 3.54 – 3.48 (m, 2H), 3.15 – 3.05 (m, *J* = 10.8 Hz, 2H), 3.00 – 2.94 (m, 1H), 2.84 – 2.79 (m, 1H), 2.21 – 2.15 (m, 1H), 1.88 – 1.79 (m, 1H), 1.71 – 1.66 (m, 2H), 1.43 – 1.34 (m, 2H), 1.32 – 1.23 (m, 1H), 1.12 – 1.01 (m, 2H), 0.95 – 0.87 (m, 1H). ¹³C NMR (126 MHz, DMSO) δ 172.2, 163.6, 157.6, 148.7, 135.8, 131.7, 129.7, 129.6, 126.8, 121.1, 113.7, 113.6, 111.3, 106.1, 79.3, 64.9, 59.8, 55.0, 34.4, 32.6, 32.1, 29.4, 28.4, 24.7, 22.0.

MS (ESI) m/z calculated for C₂₉H₃₃N₇O₃:[M]⁺: 527.27; found [M-H]⁺: 526.33.


N-(2-methoxy-4-nitrophenyl)-1-(6-oxo-5-phenyl-5,6-dihydrotetrazolo[1,5-a]pyrazin-7(8H)-yl)cyclohexanecarboxamide (11l):



The product was obtained using procedure C. Yield: 71%.

¹H NMR (500 MHz, CDCl₃) δ 8.60 (s, 1H), 8.50 (d, *J* = 9.0 Hz, 1H), 7.90 (dd, *J* = 9.0, 2.4 Hz, 1H), 7.72 (d, *J* = 2.4 Hz, 1H), 7.33 – 7.33 (m, 3H), 7.14 (dd, *J* = 7.6, 1.8 Hz, 2H), 6.23 (s, 1H), 5.31 (d, *J* = 16.5 Hz, 1H), 5.10 (d, *J* = 16.5 Hz, 1H), 3.94 (s, 3H), 2.38 – 2.17 (m, 2H), 1.89 – 1.45 (m, 6H), 1.34 – 1.23 (m, 1H), 0.90 – 0.82 (m, 1H). ¹³C NMR (126 MHz, CDCl₃) δ 171.2, 165.5, 147.7, 143.4, 133.6, 133.2, 129.8, 129.5, 126.7, 118.4, 117.7, 105.2, 67.4, 63.5, 56.5, 39.6, 32.3, 31.8, 25.0, 22.6, 22.4.




MS (ESI) m/z calculated for C₂₄H₂₅N₇O₅: [M]⁺: 491.19; found [M-H]⁺: 490.23.




TR209_1_Silica_4.6X250_MeOH_5-30%_6

TR209_1

3: Diode Array
Range: 4.451








TR210_1_Silica_4.6X250_MeOH_5-30%_6


TR210_1

3: Diode Array
Range: 7.121



TR210_1 154 (2.674) 2: Scan ES- 6.88e5








TR211_1_Silica_4.6X250_MeOH_5-30%_6


TR211_1

3: Diode Array
Range: 4.696



Chemical Formula: C₃₁H₂₉N₅O₂
Exact Mass: 503.2321






TR212_1_Silica_4.6X250_MeOH_5-30%_6


TR212_1

3: Diode Array
Range: 6.63




TR212_1


2: Scan ES-
502.23
1.98e6



TR212_1 156 (2.709)

2: Scan ES-
1.19e6







TR175_1_Silica_4.6X250_MeOH_5-30%_6


TR175_1


3: Diode Array
Range: 5.384



TR175_1 163 (2.831)

2: Scan ES- 488.22 2.28e6








TR217_1_Silica_4.6X250_MeOH_5-30%_6


TR217_1

3: Diode Array
Range: 1.051e+1





TR217_1 206 (3.577) 2: Scan ES- 541.23 2.04e6







NL: 2.14E7
TR213seg_13090913
1441#18-27 RT:
0.31-0.46 AV: 10 F:-
p ESI Q1MS
[100.000-750.000]





Chemical Formula: C₄H₇N₅O₂
Exact Mass: 157.0600





NL: 3.26E7
TR214seg_13090912
4017#18-27 RT:
0.31-0.46 AV: 10 F:-
p ESI Q1MS
[100.000-750.000]





















NL: 2.52E7
TR218seg_13090912
3517#12-17 RT:
0.20-0.28 AV: 6 F: +
p ESI Q1MS
[100.000-750.000]

Chemical Formula: C₁₀H₁₁N₅O₂
Exact Mass: 233.0913








TR228_1_Silica_4.6X250_MeOH_5-30%_6


TR228_1




3: Diode Array
Range: 1.932



TR228_1 163 (2.830)

2: Scan ES-
2.01e6









TR229 f1_1_Silica_4.6X250_MeOH_5-30%_6


TR229 f1_1

3: Diode Array
Range: 6.075



Chemical Formula: C₂₅H₂₆FN₇O₂
Exact Mass: 475.2132









TR244_1_Silica_4.6X250_MeOH_5-30%_6

TR244_1

3: Diode Array
Range: 1.19e+1






TR245 f8_1_Silica_4.6X250_MeOH_5-30%_6


TR245 f8_1

3: Diode Array
Range: 1.536




TR245 f8_1



2: Scan ES-
423.26
2.53e6



TR245 f8_1 135 (2.344)

2: Scan ES-
4.21e5






TR246 f25_1_Silica_4.6X250_MeOH_5-30%_6


TR246 f25_1


3: Diode Array
Range: 1.08e+1



TR246 f25_1 176 (3.056)

2: Scan ES- 6.42e5







TR247 f16_1_Silica_4.6X250_MeOH_5-30%_6

TR247 f16_1

3: Diode Array
Range: 1.112e+1








TR249_1_Silica_4.6X250_MeOH_5-30%_6

TR249_1

3: Diode Array
Range: 5.764







TR250 f6_1_Silica_4.6X250_MeOH_5-30%_6


TR250 f6_1


3: Diode Array
Range: 5.086



TR250 f6_1 172 (2.987)

2: Scan ES- 512.18
2.62e5






TR253_1_Silica_4.6X250_MeOH_5-30%_6

TR253_1


3: Diode Array
Range: 1.143e+1




TR253_1_Silica_4.6X250_MeOH_5-30%_6

TR253_1 201 (3.482)

1: Scan ES+ 5.94e5









TR254 f18_1_Silica_4.6X250_MeOH_5-30%_6

TR254 f18_1

3: Diode Array
Range: 1.098e+1






TR257 f22_1_Silica_4.6X250_MeOH_5-30%_6

TR257 f22_1


3: Diode Array
Range: 8.148




TR257 f22_1 157 (2.726)

437.17

2: Scan ES-
9.90e5







TR252_1_Silica_4.6X250_MeOH_5-30%_6


TR252_1

3: Diode Array
Range: 6.474



TR252_1 197 (3.421)








TR259_1_Silica_4.6X250_MeOH_5-30%_6


TR259_1

3: Diode Array
Range: 6.348



TR259_1 155 (2.692) 478.17 2: Scan ES- 8.26e4






TR256_1_Silica_4.6X250_MeOH_5-30%_6


TR256_1

3: Diode Array
Range: 6.156




TR256_1


2: Scan ES-
526.26
1.31e6



TR256_1 232 (4.029)

2: Scan ES-
5.00e5






TR258 1 Silica 4.6X250 MeOH 5-30% 6

TR258 1

3: Diode Array
Range: 5.294



Computational Library

A virtual library of 100,000 randomly generated compounds were made for each library using previously described methods (Koes, D. et al. *PLoS One* **2012**, 7, e32839.). 1000 compounds of each reaction were randomly selected and physiochemical properties relating to drug likeness were analyzed via ChemAxon's Instant JChem Software (Instant JChem 5.9.2, 2012, ChemAxon <http://www.chemaxon.com>). Principal moment of inertia was calculated using Schrodinger's Maestro V 9.3(**Suite 2012**: Maestro, version 9.3, Schrödinger, LLC, New York, NY, 2012.)

PCA Data:

Importance of components:

	PC1	PC2	PC3	PC4	PC5	PC6	PC7	PC8	PC9	PC10
Standard deviation	3.774	2.7358	1.69848	1.43924	1.27598	1.0874	1.00623	0.99	0.89896	0.81885
Proportion of Variance	0.407	0.2139	0.08242	0.05918	0.04652	0.03378	0.02893	0.028	0.02309	0.01916
Cumulative Proportion	0.407	0.6208	0.70323	0.76241	0.80893	0.84271	0.87164	0.8996	0.92273	0.94189


Rotation:

	PC1	PC2	PC3	PC4	PC5	PC6	PC7	PC8	PC9	PC10
Mass	0.258705	0.014708	-0.077005	0.023445	-0.034303	0.020495	-0.007753	0.001122	0.004544	-0.015128
donorcount	0.152854	-0.222774	0.026563	0.173554	0.088181	-0.066643	-0.069352	0.069098	0.080295	0.435077
donsitecount	0.144728	-0.231833	0.037370	0.168639	0.087503	-0.054775	-0.071318	0.069175	0.071336	0.484416
acceptorcount	0.220940	-0.089600	0.143997	0.103002	-0.024664	0.027887	-0.024726	0.040056	0.000874	-0.371341
accsitecount	0.209907	-0.134012	0.092947	0.109912	0.006882	-0.032200	-0.037850	0.037888	0.037465	-0.472966
logP	0.046896	0.273409	-0.331467	-0.036007	-0.083508	0.054038	0.007544	0.007227	0.015290	0.014617
pH0	0.021696	0.244639	-0.319969	-0.019325	-0.111630	0.033178	-0.042704	0.005074	0.061362	-0.252434
pH7	0.011278	0.288340	-0.294525	-0.064074	-0.082554	0.047474	0.013492	0.016485	0.003620	0.053433
pH14	-0.026198	0.262314	-0.243063	-0.161756	-0.112661	0.135859	-0.047475	0.043304	-0.076876	0.224523
PSA	0.220095	-0.146863	0.110381	0.133655	-0.024219	0.031618	-0.042116	0.047809	0.014107	-0.142322
Atomcount	0.250847	-0.033297	-0.128809	-0.058870	-0.037514	0.045378	-0.027288	0.014084	-0.009316	0.103476
AliphaticAtomCount	0.202419	-0.192790	-0.133416	-0.176500	-0.049634	0.052915	-0.037071	0.034388	-0.017106	0.007181
AromaticAtomCount	0.163352	0.250225	0.050071	0.240062	0.027820	-0.052066	-0.033462	0.041264	0.031952	-0.019939
BondCount	0.253622	-0.017187	-0.115512	-0.061356	-0.028391	0.034839	-0.023869	0.012468	-0.006580	0.101253
AliphaticBondCount	0.222586	-0.151350	-0.114543	-0.185382	-0.031864	0.027118	-0.030067	0.031687	-0.009455	-0.001171
AromaticBondCount	0.160495	0.253328	0.058645	0.244296	0.031566	-0.048922	-0.033617	0.042700	0.030155	-0.002148
RotatableBondCount	0.211434	-0.125220	-0.133187	0.065362	-0.194420	0.158503	-0.041647	0.008710	-0.042614	0.049979
RingCount	0.205950	0.202513	0.099602	-0.073924	0.102245	-0.116749	-0.029500	0.013145	0.031956	0.037975
AliphaticRingCount	0.130283	-0.040139	0.042061	-0.527364	0.172060	-0.199537	0.009889	0.040129	0.036707	0.028700
AromaticRingCount	0.158033	0.257058	0.089085	0.233677	0.013572	-0.013642	-0.027937	0.039359	0.014556	0.026313
HeteroRingCount	0.160335	0.126946	0.332753	-0.123855	-0.010302	0.156726	-0.118133	0.098985	-0.152745	0.042251
HeteroaliphaticRingCount	0.157307	-0.067008	0.072142	-0.359287	0.175691	-0.189145	-0.142307	0.179238	-0.027425	-0.105514
HeteroaromaticRingCount	0.084376	0.193998	0.343983	0.092701	-0.128791	0.310169	-0.0446343	0.002438	-0.161678	0.119820
RingAtomCount	0.215114	0.187560	0.040753	-0.017348	0.149256	-0.131513	-0.028691	0.015648	0.052886	0.034913
RingBondCount	0.212434	0.194588	0.056875	-0.030471	0.145560	-0.128706	-0.026341	0.012754	0.049970	0.030609

ChainAtomCount	0.187737	-0.192686	-0.165671	0.066447	-0.214460	0.169376	-0.044828	0.016533	-0.050094	-0.056006
ChainBondCount	0.212262	-0.157556	-0.156116	0.062970	-0.185363	0.139208	-0.034746	0.010183	-0.040253	-0.041406
SmallestRingSize	-0.042525	-0.093518	-0.255180	0.235165	0.443817	0.013961	-0.121878	0.093220	-0.355634	-0.047239
LargestRingSize	0.037893	0.019578	-0.074393	-0.041934	0.532188	0.429119	-0.065082	0.077368	-0.440503	-0.044982
RingCountofSize4	0.015133	-0.001250	0.026083	-0.218592	-0.146152	-0.095385	-0.565537	0.649941	-0.322431	-0.007838
RingCountofSize5	0.092818	0.161856	0.319175	-0.206161	-0.156799	0.229359	-0.093989	0.137379	-0.114021	0.081719
RingCountofSize6	0.192218	0.142342	-0.099602	0.098052	0.226325	-0.343501	-0.044012	0.010367	0.075410	-0.009788
RingCountofSize7	-0.008600	0.018298	-0.009621	-0.118770	0.274441	0.387261	-0.308256	0.549630	0.566695	-0.035844
RingCountofSize8	0.006500	-0.020502	-0.000605	-0.043791	0.179761	0.346878	0.697536	0.415271	0.382244	-0.022576
VDWVol	0.257403	-0.008683	-0.118251	-0.016344	-0.036393	0.033506	-0.019511	0.008745	-0.003306	0.052294

Single Crystal X-Ray Structure Determination of Compounds

Structure determination of compound **1e**



Structure determination of compound **5n**

